Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) and Soligenix (NASDAQ:SNGX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.
Insider and Institutional Ownership
8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by insiders. Comparatively, 1.9% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Lisata Therapeutics and Soligenix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
| Soligenix | 1 | 0 | 0 | 0 | 1.00 |
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -116.08% | -90.55% |
| Soligenix | N/A | -180.25% | -107.46% |
Valuation and Earnings
This table compares Lisata Therapeutics and Soligenix”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | $170,000.00 | 87.45 | -$16.59 million | ($1.64) | -1.01 |
| Soligenix | $120,000.00 | 46.93 | -$11.08 million | ($0.98) | -0.39 |
Soligenix has lower revenue, but higher earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Lisata Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.
Summary
Lisata Therapeutics beats Soligenix on 7 of the 11 factors compared between the two stocks.
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
About Soligenix
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
